(Q47742599)

http://europepmc.org/abstract/MED/28948977

5 February 2018

title

Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others (English)

1 reference

http://europepmc.org/abstract/MED/28948977

5 February 2018

author

David P. Lane

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28948977%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

author name string

Kanaga Sabapathy

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28948977%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

language of work or name

English

0 references

publication date

26 September 2017

1 reference

http://europepmc.org/abstract/MED/28948977

5 February 2018

published in

Nature Reviews Clinical Oncology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28948977%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28948977%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28948977%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

page(s)

13-30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28948977%20AND%20SRC:MED&resulttype=core&format=json

Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas

31 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

p53 mutations in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Discovery and saturation analysis of cancer genes across 21 tumour types

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Tumor suppressive functions of p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Unravelling mechanisms of p53-mediated tumour suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

p53 in survival, death and metabolic health: a lifeguard with a licence to kill

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

p53 in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

The expanding universe of p53 targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

The mitochondrial p53 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Tumor spectrum analysis in p53-mutant mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Insights into wild-type and mutant p53 functions provided by genetically engineered mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Cell-type, dose, and mutation-type specificity dictate mutant p53 functions in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

p53 efficiently suppresses tumor development in the complete absence of its cell-cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Targeting p53 for enhanced radio- and chemo-sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

p53 as an Effector or Inhibitor of Therapy Response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Does p53 status influence tumor response to anticancer therapies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

p53 and hereditary cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Linking environmental carcinogen exposure to TP53 mutations in human tumours using the human TP53 knock-in (Hupki) mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

TP53 mutations in human cancers: origins, consequences, and clinical use

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

TP53 and gastric carcinoma: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Prevalence of allelic loss at TP53 in endometrial carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

The rebel angel: mutant p53 as the driving oncogene in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

TP53 Mutations in Head and Neck Squamous Cell Carcinoma and Their Impact on Disease Progression and Treatment Response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

TP53 Mutational Analysis Enhances the Prognostic Accuracy of IHC4 and PAM50 Assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Structure-function-rescue: the diverse nature of common p53 cancer mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

21 January 2018

p53 mutations in cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Mutant p53: one name, many proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

The role of mutant p53 in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Direct regulation of the centrosome duplication cycle by the p53-p21Waf1/Cip1 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Mutant p53 drives multinucleation and invasion through a process that is suppressed by ANKRD11.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Fischer-344 Tp53-knockout rats exhibit a high rate of bone and brain neoplasia with frequent metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

tp53 mutant zebrafish develop malignant peripheral nerve sheath tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

The evolution of thymic lymphomas in p53 knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Mutant p53(R270H) gain of function phenotype in a mouse model for oncogene-induced mammary carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Li-Fraumeni syndrome: cancer risk assessment and clinical management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Unequal prognostic potentials of p53 gain-of-function mutations in human cancers associate with drug-metabolizing activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Clinical relevance of gain-of-function mutations of p53 in high-grade serous ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Identification of a novel p53 functional domain that is necessary for efficient growth suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Four domains of p300 each bind tightly to a sequence spanning both transactivation subdomains of p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Rearrangements of the cellular p53 gene in erythroleukaemic cells transformed by Friend virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Deletion of 5'-coding sequences of the cellular p53 gene in mouse erythroleukemia: a novel mechanism of oncogene regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Amino-terminal p53 mutations lead to expression of apoptosis proficient p47 and prognosticate better survival, but predispose to tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

DeltaN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Dissecting functional roles of p53 N-terminal transactivation domains by microarray expression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

The N-terminally truncated p53 isoform Δ40p53 influences prognosis in mucinous ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Characterization of p53 oligomerization domain mutations isolated from Li-Fraumeni and Li-Fraumeni like family members

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

p53 Oligomerization is essential for its C-terminal lysine acetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Disruption of an intermonomer salt bridge in the p53 tetramerization domain results in an increased propensity to form amyloid fibrils.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Screening the p53 status of human cell lines using a yeast functional assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

The Contrived Mutant p53 Oncogene - Beyond Loss of Functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Cancer-derived p53 mutants suppress p53-target gene expression--potential mechanism for gain of function of mutant p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Oncogenic forms of p53 inhibit p53-regulated gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

The R246S hot-spot p53 mutant exerts dominant-negative effects in embryonic stem cells in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

How many mutant p53 molecules are needed to inactivate a tetramer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Gain of function mutations in p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Mutant p53-R273H mediates cancer cell survival and anoikis resistance through AKT-dependent suppression of BCL2-modifying factor (BMF).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

A Pin1/mutant p53 axis promotes aggressiveness in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Promyelocytic leukemia protein is required for gain of function by mutant p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Tumor-derived p53 mutants induce NF-kappaB2 gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor β signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Mutant p53 drives invasion by promoting integrin recycling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Activation of the cryptic DNA binding function of mutant forms of p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Small peptides activate the latent sequence-specific DNA binding function of p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Assessing the Efficacy of Mdm2/Mdm4-Inhibiting Stapled Peptides Using Cellular Thermal Shift Assays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Drugging the p53 pathway: understanding the route to clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Clinical Overview of MDM2/X-Targeted Therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Restoration of wild-type conformation and activity of a temperature-sensitive mutant of p53 (p53(V272M)) by the cytoprotective aminothiol WR1065 in the esophageal cancer cell line TE-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Mutant p53 targeting by the low molecular weight compound STIMA-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Targeted rescue of a destabilized mutant of p53 by an in silico screened drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

SCH529074, a small molecule activator of mutant p53, which binds p53 DNA binding domain (DBD), restores growth-suppressive function to mutant p53 and interrupts HDM2-mediated ubiquitination of wild type p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Allele-specific p53 mutant reactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Small molecule induced reactivation of mutant p53 in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Small-Molecule Reactivation of Mutant p53 to Wild-Type-like p53 through the p53-Hsp40 Regulatory Axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Reactivation of mutant p53 by a dietary-related compound phenethyl isothiocyanate inhibits tumor growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Mutant p53 reactivation by small molecules makes its way to the clinic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Synthetic metallochaperone ZMC1 rescues mutant p53 conformation by transporting zinc into cells as an ionophore

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Active Pin1 is a key target of all-trans retinoic acid in acute promyelocytic leukemia and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Characterization of a 54K Dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

T antigen is bound to a host protein in SY40-transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Targeting the ERBB family in cancer: couples therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Energy Requirement for Degradation of Tumor-Associated Protein p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

PRIMA-1MET induces nucleolar translocation of Epstein-Barr virus-encoded EBNA-5 protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

An in silico algorithm for identifying stabilizing pockets in proteins: test case, the Y220C mutant of the p53 tumor suppressor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Prognostic implications of circulating anti-p53 antibodies in lung cancer--a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Phase I dendritic cell p53 peptide vaccine for head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Awaiting a new era of cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Next-generation sequencing to guide cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

The first five years of single-cell cancer genomics and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Design of a molecular support for cryo-EM structure determination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Participation of p53 cellular tumour antigen in transformation of normal embryonic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Cellular immortalization by a cDNA clone encoding the transformation-associated phosphoprotein p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Reconstitution of p53 expression in a nonproducer Ab-MuLV-transformed cell line by transfection of a functional p53 gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

The p53 proto-oncogene can act as a suppressor of transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Wild-type p53 can inhibit oncogene-mediated focus formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Modulation of p53 protein conformation and DNA-binding activity by intracellular chelation of zinc.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

The clonal and mutational evolution spectrum of primary triple-negative breast cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Resistance to DNA-damaging agents is discordant from experimental metastatic capacity in MEF ras-transformants-expressing gain of function MTp53

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

The differential effects of mutant p53 alleles on advanced murine lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Two tandem and independent sub-activation domains in the amino terminus of p53 require the adaptor complex for activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

p53 Stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Simple identification of dominant p53 mutants by a yeast functional assay

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Dosage-dependent dominance over wild-type p53 of a mutant p53 isolated from nasopharyngeal carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Tumour-associated mutant p53 drives the Warburg effect

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Pharmacological rescue of mutant p53 conformation and function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Mining the National Cancer Institute Anticancer Drug Discovery Database: cluster analysis of ellipticine analogs with p53-inverse and central nervous system-selective patterns of activity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.151

7 January 2021

inferred from DOI database lookup

p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis

1 reference

12 December 2020

Regulation of the level of the oncoprotein p53 in non-transformed and transformed cells.

1 reference

12 December 2020

A germline 2.35 kb deletion of p53 genomic DNA creating a specific loss of the oligomerization domain inherited in a Li-Fraumeni syndrome family

1 reference

12 December 2020

Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse

1 reference

12 December 2020

P53 mutations in colorectal cancer assessed in both genomic DNA and cDNA as compared to the presence of p53 LOH

1 reference

12 December 2020

Simian virus 40-transformed cells express new species of proteins precipitable by anti-simian virus 40 tumor serum

1 reference

12 December 2020

Role of tyrosine kinase inhibitors in cancer therapy

1 reference

12 December 2020

Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator.

1 reference

12 December 2020

COOH-terminal domain of p53 modulates p53-mediated transcriptional transactivation, cell growth, and apoptosis.

1 reference

12 December 2020

The application of gene therapy in China.

1 reference

12 December 2020

Induction of gene amplification as a gain-of-function phenotype of mutant p53 proteins

1 reference

12 December 2020

10.1038/NRCLINONC.2017.151

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28948977%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

1 reference